@article {Tandan2020.07.03.20146035, author = {Nitin Tandan and Manjari Rani Regmi and Ruby Maini and Abdisamad M. Ibrahim and Cameron Koester and Odalys Estefania Lara Garcia and Priyanka Parajuli and Mohammad Al-Akchar and Mukul Bhattarai and Abhishek Kulkarni and Robert Robinson}, title = {Age Matters: COVID-19 Prevalence in a Vaping Adolescent Population {\textendash} An Observational Study}, elocation-id = {2020.07.03.20146035}, year = {2020}, doi = {10.1101/2020.07.03.20146035}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Currently, there is limited or no data demonstrating that vaping is associated with increased transmission or prevalence of coronavirus disease-2019 (COVID-19). Our study aims to investigate the relationship of vaping with the prevalence of COVID-19 infection across the United States and in the District of Columbia.Methods COVID-19 case counts by state and the District of Columbia were obtained via the Worldometers website on 04/30/2020. Prevalence of COVID-19 cases per 100,000 residents were calculated using estimated 2019 population data from the US Census Department. Age ranges analyzed were: high school age children, Ages 18-24, Ages 25-44, and Ages 45-65. Spearman correlation analysis was conducted to determine if the rate of vaping was correlated with a higher prevalence of COVID-19 cases per 100,000 population.Findings The Spearman correlation analysis demonstrated that persons vaping between 18 years and 24 years of age had a correlation coefficient of 0.278 with prevalence of COVID-19 infection (p=0.048). Vaping high school students had a correlation coefficient of 0.153 with prevalence of COVID-19 (p=0.328). Persons vaping in the age group 25-45 years had a correlation coefficient of 0.101 in association to COVID-19 prevalence (p=0.478). And finally, persons vaping between the age 45-65 years old had a correlation coefficient 0.130 with respect to COVID-19 prevalence (p=0.364).Interpretation Increased COVID-19 prevalence is associated with vaping in the adolescent population between ages 18 and 24. Further prospective studies need to be performed in order investigate the severity of outcomes of vaping in association with COVID-19 infection.Funding Nothing to disclose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere are no funding sources to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No direct patient care or contact involved in this observational study thus the study was exempt from IRB oversight. Institution Review Board: SCRIHS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this study is available in the public domain. Thus, there is no limitation in obtaining and reviewing the data provided in this manuscript.}, URL = {https://www.medrxiv.org/content/early/2020/07/04/2020.07.03.20146035}, eprint = {https://www.medrxiv.org/content/early/2020/07/04/2020.07.03.20146035.full.pdf}, journal = {medRxiv} }